US EditionNew Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
The open, single-arm, prospective phase IIIb ARTIOS study showed a substantial reduction in disease activity in people with recurrent multiple sclerosis (RMS) following the change to Kesimpta®, after presenting disease activity* with fingolimod or fumarate-based therapies. Novartis today announced new data from two studies with Kesimpta® (ofatumumab) in recurrent multiple sclerosis (RMS), to be presented at the Annual Congress of the European Co…
Novartis releases new data on benefits of Kesimpta in relapsing multiple sclerosis - Express Pharma
Novartis has released new data from two Kesimpta (ofatumumab) studies in relapsing multiple sclerosis (RMS) that will be presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2025 Annual Meeting in Barcelona, Spain, on September 24–26. Data from the ARTIOS Phase IIIb, open-label, single-arm, prospective study showed that patients who switched to Kesimpta after breakthrough disease on fingolimod or fumarat…
New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after breakthrough disease* on fingolimod or fumarate-based therapies1Following switch to Kesimpta, over 90% of people…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
